Patents Assigned to Reveragen Biopharma, Inc
  • Non-hormonal steroid modulators of NF-kB for treatment of disease
    Patent number: 11833159
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: December 5, 2023
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Non-hormonal steroid modulators of NF-?? for treatment of disease
    Patent number: 11690853
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: July 4, 2023
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju, Jesse Damsker
  • Aqueous oral pharmaceutical suspension compositions
    Patent number: 11471471
    Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.
    Type: Grant
    Filed: February 21, 2022
    Date of Patent: October 18, 2022
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John McCall, Jesse Damsker
  • Aqueous oral pharmaceutical suspension compositions
    Patent number: 11382922
    Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: July 12, 2022
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John McCall, Jesse Damsker
  • Non-hormonal steroid modulators of NF-kB for treatment of disease
    Patent number: 10857161
    Abstract: Provided herein is a pharmaceutical composition comprising a compound having the structural formula wherein the compound is present in an amount effective to treat or reduce the symptoms of muscular dystrophy. The therapeutically effective amount may be between 10 mg to 200 mg, or may be between 0.01 mg/kg to 10.0 mg/kg. Also provided are methods of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective of the above compound.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 8, 2020
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
    Patent number: 10799514
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: October 13, 2020
    Assignee: Reveragen Biopharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju, Jesse Damsker
  • Non-hormonal steroid modulators of NF-?? for treatment of disease
    Patent number: 10464967
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: November 5, 2019
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Nagaraju (Raju) Kanneboyina, Jesse Damsker
  • Non-hormonal steroid modulators of NF-kB for treatment of disease
    Patent number: 10206933
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: February 19, 2019
    Assignee: ReveraGen Biopharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Non-hormonal steroid modulators of NF-?B for treatment of disease
    Patent number: 10000525
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: June 19, 2018
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Non-hormonal steroid modulators of NF-?B for treatment of disease
    Patent number: 9649320
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: May 16, 2017
    Assignee: ReveraGen Biopharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Methods and agents to increase therapeutic dystrophin expression in muscle
    Patent number: 9637738
    Abstract: Agents and methods for increasing dystrophin protein expression in muscle through blocking of specific microRNAs and microRNA binding sites on the dystrophin 3? untranslated region (miR-146a, miRNA-146b, miR-223, miR-320a, miR374a, and miR-382). Methods for increasing the amount of dystrophin useful for effective therapeutic intervention for Becker muscular dystrophy, Duchenne muscular dystrophy, and other disorders where loss of dystrophin from muscle causes pathology.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: May 2, 2017
    Assignee: Reveragen Biopharma, Inc.
    Inventors: Eric Hoffman, Alyson Fiorillo
  • Non-hormonal steroid modulators of NF-?B for treatment of disease
    Patent number: 9434758
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: September 6, 2016
    Assignee: ReveraGen Biopharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Non-hormonal steroid modulators of NF-?B for treatment of disease
    Patent number: 9198921
    Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: December 1, 2015
    Assignee: ReveraGen BioPharma, Inc.
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
  • Non-hormonal steroid modulators of NF-kB for treatment of disease
    Patent number: 8673887
    Abstract: The present invention relates to compounds and methods which may be useful for the treatment of inflammatory bowel disease, Crohn's disease and colitis.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: March 18, 2014
    Assignee: Reveragen Biopharma, Inc
    Inventors: John M. McCall, Eric Hoffman, Kanneboyina Nagaraju